Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
I-MAK Files Patent Challenge on Hepatitis C drug Sofosbuvir in India
Gilead attempt to secure patent on hepatitis C drug opposed in India
Patent war: patients vs profit – Tahir Amin Discusses the Recent Novartis Decision on NDTV
Low-Cost Drugs in Poor Nations Get a Lift in Indian Court (New York Times)
Indian court ruling hailed as victory for generic drugs (Los Angeles Times)
The Op-Ed: India Deals A Blow to Pharma’s Life Cycle Strategy (Pharmalot)
US business groups say verdict to impact pharma innovation in India (Business Standard)
The Indian Supreme Court Weighs In on Patent Evergreening (Health Affairs Blog)
The Hypocrisy of Novartis (Mumbai Mirror)
Only 3% of patents filed by MNC pharma firms under dispute: Study (Economic Times)